Early renal injury after myeloablative cord blood transplantation in adults

Hiroshi Mae Department of Pharmacy

Jun Ooi Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, Tokyo, JapanCorrespondence[email protected]

, MD,

Satoshi Takahashi Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Akira Tomonari Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Nobuhiro Tsukada Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Takaaki Konuma Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Emi Hongo Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Seiko Kato Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Senji Kasahara Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Maki Oiwa-Monna Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Yosuke Kurokawa Department of Pharmacy

Arinobu Tojo Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Shigetaka Asano Department of Hematology and Oncology, Institute of Medical Science, University of Tokyo, Tokyo, Japan

show all

Abstract

We report a retrospective analysis of acute renal failure (ARF) in a group of 54 adult patients with hematological malignancies treated with unrelated cord blood transplantation (CBT) after myeloablative conditioning. All patients received four fractionated 12 Gy total body irradiation and chemotherapy as myeloablative conditioning. ARF was defined as the doubling serum creatinine occurring within the first 100 days after CBT. A statistically significant decrement of renal function from baseline was observed in days between 11 and 20. ARF occurred in 27.8% of patients. Although no difference was seen in maximum cyclosporine trough levels, the maximum of vancomycin (VCM) trough levels were significantly higher in patients with ARF (p = 0.01). Our result suggests that it is important to monitor VCM dosing more strictly with pharmacokinetic assessment, especially in days 11 – 20, when the most frequently observed declining renal function.

Keywords:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Early renal injury after myeloablative cord blood transplantation in adults

Information for

Open access

Opportunities

Help and information

Early renal injury after myeloablative cord blood transplantation in adults

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature